Corautus Announces Contract With PPD for GENASIS Gene Therapy Trial

Corautus Genetics has selected PPD to provide certain clinical research services for GENASIS (Genetic Angiogenic Stimulation Investigational Study), Corautus' Phase IIb clinical trial to evaluate the safety and efficacy of vascular endothelial growth factor-2 for the treatment of patients with severe angina.

Under the terms of the agreement, PPD, a leading global provider of discovery and development services and products to pharmaceutical, biotechnology and medical device companies, will provide Corautus with medical monitoring, data management, biostatistics services and final study reporting for the GENASIS trial.

GENASIS will enroll 404 patients with Class III or IV angina that are not suitable candidates for traditional revascularization procedures. The GENASIS trial will be conducted in approximately 25 cardiac medical centers throughout the U.S.